O	0	5	Phase
O	6	8	II
O	8	9	,
O	10	16	double
O	16	17	-
O	17	22	blind
O	22	23	,
O	24	34	randomized
O	35	40	trial
O	41	43	of
B-intervention	44	56	capecitabine
I-intervention	57	61	plus
I-intervention	62	73	enzastaurin
O	74	80	versus
B-control	81	93	capecitabine
I-control	94	98	plus
I-control	99	106	placebo
O	107	109	in
B-eligibility	110	118	patients
I-eligibility	119	123	with
I-eligibility	124	134	metastatic
I-eligibility	135	137	or
I-eligibility	138	147	recurrent
I-eligibility	148	154	breast
I-eligibility	155	161	cancer
I-eligibility	162	167	after
I-eligibility	168	173	prior
I-eligibility	174	187	anthracycline
I-eligibility	188	191	and
I-eligibility	192	198	taxane
I-eligibility	199	206	therapy
O	206	207	.

O	208	220	Capecitabine
O	221	223	is
O	224	234	frequently
O	235	239	used
O	240	242	in
O	243	246	the
O	247	256	treatment
O	257	259	of
O	260	269	recurrent
O	269	270	/
O	270	281	progressive
O	282	292	metastatic
O	293	299	breast
O	300	306	cancer
O	307	308	(
O	308	311	MBC
O	311	312	)
O	313	318	after
O	319	324	prior
O	325	338	anthracycline
O	339	342	and
O	343	349	taxane
O	350	357	therapy
O	357	358	.

O	359	363	With
O	364	367	the
O	368	377	intention
O	378	380	of
O	381	390	improving
O	391	394	the
O	395	403	efficacy
O	404	406	of
O	407	413	single
O	414	419	agent
O	420	432	capecitabine
O	432	433	,
O	434	436	we
O	437	446	initiated
O	447	448	a
O	449	459	randomized
O	459	460	,
O	461	467	double
O	467	468	-
O	468	473	blind
O	473	474	,
O	475	482	placebo
O	482	483	-
O	483	493	controlled
O	494	499	Phase
O	500	502	II
O	503	508	study
O	509	511	of
O	512	515	the
O	516	521	novel
O	522	528	serine
O	528	529	/
O	529	538	threonine
O	539	545	kinase
O	546	555	inhibitor
O	556	567	enzastaurin
O	568	570	in
O	571	582	combination
O	583	587	with
O	588	600	capecitabine
O	601	603	in
O	604	605	a
O	606	613	heavily
O	614	624	pretreated
O	625	632	patient
O	633	643	population
O	643	644	.

O	645	653	Patients
O	654	662	received
O	663	675	capecitabine
O	676	677	1
O	677	678	,
O	678	681	250
O	682	684	mg
O	684	685	/
O	685	686	m
O	686	687	(
O	687	688	2
O	688	689	)
O	690	695	twice
O	696	701	daily
O	702	706	plus
O	707	718	enzastaurin
O	719	722	500
O	723	725	mg
O	725	726	/
O	726	729	day
O	729	730	,
O	731	733	or
O	734	746	capecitabine
O	747	751	plus
O	752	759	placebo
O	759	760	.

O	761	764	The
O	765	777	capecitabine
O	778	781	was
O	782	794	administered
O	795	798	for
O	799	802	the
O	803	808	first
O	809	811	14
O	812	816	days
O	817	819	of
O	820	824	each
O	825	827	21
O	828	831	day
O	832	837	cycle
O	837	838	.

O	839	842	The
O	843	850	primary
O	851	858	outcome
O	859	862	was
B-outcome-Measure	863	874	progression
I-outcome-Measure	874	875	-
I-outcome-Measure	875	879	free
I-outcome-Measure	880	888	survival
I-outcome-Measure	889	890	(
I-outcome-Measure	890	893	PFS
I-outcome-Measure	893	894	)
O	895	900	using
O	901	904	the
O	905	908	log
O	908	909	-
O	909	913	rank
O	914	918	test
O	919	920	(
O	920	921	1
O	921	922	-
O	922	927	sided
O	928	940	significance
O	941	946	level
O	947	949	of
O	950	951	0
O	951	952	.
O	952	954	20
O	954	955	)
O	955	956	.

O	957	959	Of
B-total-participants	960	963	109
O	964	972	patients
O	973	981	assessed
O	982	985	for
O	986	997	eligibility
O	997	998	,
B-total-participants	999	1001	85
O	1002	1006	were
O	1007	1015	enrolled
O	1015	1016	,
O	1017	1027	randomized
O	1027	1028	,
O	1029	1032	and
O	1033	1040	treated
O	1041	1042	(
B-intervention-participants	1042	1044	42
O	1045	1048	and
B-control-participants	1049	1051	43
O	1052	1060	patients
O	1061	1063	in
O	1064	1068	each
O	1069	1079	respective
O	1080	1089	treatment
O	1090	1095	group
O	1095	1096	)
O	1096	1097	.

O	1098	1101	The
O	1102	1107	study
O	1108	1111	was
O	1112	1122	terminated
O	1123	1128	early
O	1129	1138	following
O	1139	1140	a
O	1141	1151	preplanned
O	1152	1160	futility
O	1161	1169	analysis
O	1169	1170	.

B-outcome	1171	1177	Median
I-outcome	1178	1181	PFS
O	1182	1183	(
O	1183	1185	95
O	1185	1186	%
O	1187	1189	CI
O	1189	1190	)
O	1191	1194	was
B-iv-cont-median	1195	1196	2
I-iv-cont-median	1196	1197	.
I-iv-cont-median	1197	1198	8
O	1199	1200	(
O	1200	1201	2
O	1201	1202	.
O	1202	1203	1
O	1203	1204	-
O	1204	1205	4
O	1205	1206	.
O	1206	1207	6
O	1207	1208	)
O	1209	1215	months
O	1216	1220	with
O	1221	1233	capecitabine
O	1234	1238	plus
O	1239	1250	enzastaurin
O	1251	1257	versus
B-cv-cont-median	1258	1259	4
I-cv-cont-median	1259	1260	.
I-cv-cont-median	1260	1261	3
O	1262	1263	(
O	1263	1264	2
O	1264	1265	.
O	1265	1266	9
O	1266	1267	-
O	1267	1268	6
O	1268	1269	.
O	1269	1270	2
O	1270	1271	)
O	1272	1278	months
O	1279	1283	with
O	1284	1296	capecitabine
O	1297	1301	plus
O	1302	1309	placebo
O	1310	1311	(
O	1311	1319	adjusted
O	1320	1326	hazard
O	1327	1332	ratio
O	1332	1333	:
O	1334	1335	1
O	1335	1336	.
O	1336	1339	728
O	1340	1341	[
O	1341	1342	1
O	1342	1343	.
O	1343	1345	00
O	1345	1346	-
O	1346	1347	2
O	1347	1348	.
O	1348	1350	97
O	1350	1351	]
O	1351	1352	;
O	1353	1354	P
O	1355	1356	=
O	1357	1358	0
O	1358	1359	.
O	1359	1362	048
O	1362	1363	)
O	1363	1364	.

B-outcome	1365	1371	Median
I-outcome	1372	1379	overall
I-outcome	1380	1388	survival
O	1389	1390	(
O	1390	1392	95
O	1392	1393	%
O	1394	1396	CI
O	1396	1397	)
O	1398	1401	was
O	1402	1407	lower
O	1408	1412	with
O	1413	1425	capecitabine
O	1426	1430	plus
O	1431	1442	enzastaurin
O	1443	1447	than
O	1448	1452	with
O	1453	1465	capecitabine
O	1466	1470	plus
O	1471	1478	placebo
O	1479	1480	(
B-iv-cont-median	1480	1481	9
I-iv-cont-median	1481	1482	.
I-iv-cont-median	1482	1483	9
O	1484	1485	[
O	1485	1486	7
O	1486	1487	.
O	1487	1488	0
O	1488	1489	-
O	1489	1491	16
O	1491	1492	.
O	1492	1493	6
O	1493	1494	]
O	1495	1501	months
O	1502	1504	vs
B-cv-cont-median	1505	1507	14
I-cv-cont-median	1507	1508	.
I-cv-cont-median	1508	1509	9
O	1510	1511	[
O	1511	1512	9
O	1512	1513	.
O	1513	1514	9
O	1514	1515	-
O	1515	1517	19
O	1517	1518	.
O	1518	1519	3
O	1519	1520	]
O	1521	1527	months
O	1527	1528	,
O	1529	1530	P
O	1531	1532	=
O	1533	1534	0
O	1534	1535	.
O	1535	1538	181
O	1538	1539	)
O	1539	1540	.

B-outcome	1541	1546	Grade
I-outcome	1547	1548	3
I-outcome	1548	1549	/
I-outcome	1549	1550	4
I-outcome	1551	1558	adverse
I-outcome	1559	1565	events
O	1566	1570	were
O	1571	1575	more
O	1576	1584	frequent
O	1585	1589	with
O	1590	1602	capecitabine
O	1603	1607	plus
O	1608	1619	enzastaurin
O	1620	1621	(
B-iv-bin-percent	1621	1623	42
I-iv-bin-percent	1623	1624	.
I-iv-bin-percent	1624	1625	9
I-iv-bin-percent	1625	1626	%
O	1627	1629	vs
B-cv-bin-percent	1630	1632	32
I-cv-bin-percent	1632	1633	.
I-cv-bin-percent	1633	1634	6
I-cv-bin-percent	1634	1635	%
O	1635	1636	)
O	1636	1637	.

O	1638	1643	Given
O	1644	1647	the
O	1648	1652	lack
O	1653	1655	of
O	1656	1659	PFS
O	1660	1667	benefit
O	1667	1668	,
O	1669	1681	capecitabine
O	1682	1686	plus
O	1687	1698	enzastaurin
O	1699	1701	is
O	1702	1712	unsuitable
O	1713	1715	as
O	1716	1723	therapy
O	1724	1727	for
O	1728	1736	patients
O	1737	1741	with
O	1742	1751	recurrent
O	1751	1752	/
O	1752	1763	progressive
O	1764	1767	MBC
O	1768	1773	after
O	1774	1779	prior
O	1780	1793	anthracycline
O	1794	1797	and
O	1798	1804	taxane
O	1805	1812	therapy
O	1812	1813	.

O	1814	1818	This
O	1819	1824	trial
O	1825	1827	is
O	1828	1838	registered
O	1839	1841	on
O	1842	1845	www
O	1845	1846	.
O	1847	1861	clinicaltrials
O	1861	1862	.

O	1863	1866	gov
O	1867	1868	(
O	1868	1878	identifier
O	1878	1879	:
O	1880	1891	NCT00437294
O	1891	1892	)
O	1892	1893	.
